4819 Emperor Blvd, Suite 400
About Kriya Therapeutics
Kriya is a next generation gene therapy company focused on expanding the field to new frontiers. It has built a fully-integrated technology enabled platform for rational vector design, analytical testing, and scalable manufacturing to design and develop gene therapies for diseases with well-understood underlying biology. The company’s proprietary computational platform, SIRVETM, supports its approach to de novo vector design, targeted sequence modification, and data analysis. Kriya believes that rationally engineered gene therapies can address a broad universe of diseases – and it is prepared and equipped to lead this new revolution in medicine.
3 articles with Kriya Therapeutics
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
Kriya Therapeutics , a next generation gene therapy company focused on developing transformative treatments for highly prevalent diseases, announced today that its CEO, Shankar Ramaswamy, M.D., will present at multiple upcoming healthcare conferences in September and October. These includ
Kriya Therapeutics announces the establishment of its internal manufacturing facility for process development and scalable cGMP production of gene therapies for prevalent serious diseases
51,350 square foot operational manufacturing facility based in Research Triangle Park, North Carolina is designed to have its own fully integrated process development lab, pilot production suite, and current good manufacturing practice (cGMP) production capability